Product Information
TIMOLOL 0.5% GEL-SOLUTION is a generic product labeled by Bausch & Lomb Americas Inc., priced at $8.3020 per ML under NDC 82260081905. Its NADAC has been published 112 times since Aug 14, 2024.
FDA first approved this application on Nov 4, 1993. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Timolol Maleate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
5 mg/mL
Manufacturer
Bausch & Lomb Americas Inc.NDC
82260081905
Classification
Generic
Dosage Form
SOLUTION
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
TIMOLOL MALEATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA020330FDA Approved
11/4/1993
TE Code
AB
On Market Since
2/14/2018
Pharmacological Classes
Price Statistics
The NADAC for TIMOLOL 0.5% GEL-SOLUTION has been published 112 times since Aug 14, 2024, and over the history we have for it it has declined 25.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.3020 per ML |
|---|---|
| All-time high | $19.0548 (Oct 16, 2024) |
| All-time low | $8.3020 (Sep 23, 2026) |
| 52-week high | $13.9013 |
| 52-week low | $8.3020 |
| Median price | $13.1291 |
| Average price | $12.9891 |
| Largest weekly change | +60.2% (Aug 21, 2024) |
| Weeks tracked | 112 |
| Tracking since | Aug 14, 2024 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 91% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Americas Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Timolol Maleate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta-Adrenergic Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TIMOLOL 0.5% GEL-SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for TIMOLOL 0.5% GEL-SOLUTION, manufactured by Bausch & Lomb Americas Inc., is $8.3020 per ML (NDC 82260081905), effective Sep 30, 2026.
How has the price of TIMOLOL 0.5% GEL-SOLUTION changed over time?
Over the history we have for it, the NADAC for TIMOLOL 0.5% GEL-SOLUTION has declined 25.5%. It has been tracked across 112 weekly CMS publications since Aug 14, 2024.
What are the highest and lowest recorded NADAC prices for TIMOLOL 0.5% GEL-SOLUTION?
Since Aug 14, 2024, the NADAC for TIMOLOL 0.5% GEL-SOLUTION has ranged from a low of $8.3020 (Sep 23, 2026) to a high of $19.0548 (Oct 16, 2024), with a median of $13.1291 per ML.
Are there cheaper alternatives to TIMOLOL 0.5% GEL-SOLUTION?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TIMOLOL MALEATE 0.5% EYE DROPS, is $0.7197 per ML — about 91% below TIMOLOL 0.5% GEL-SOLUTION.
Who manufactures TIMOLOL 0.5% GEL-SOLUTION?
TIMOLOL 0.5% GEL-SOLUTION (NDC 82260081905) is labeled by Bausch & Lomb Americas Inc., and CMS classifies it as a generic product.